Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts.
DU-145
PC3
hypoxia
hypoxia gene signature
pre-clinical models
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 May 2021
26 May 2021
Historique:
received:
30
04
2021
revised:
21
05
2021
accepted:
22
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
This pre-clinical study was designed to refine a dissection method for validating the use of a 15-gene hypoxia classifier, which was previously established for head and neck squamous cell carcinoma (HNSCC) patients, to identify hypoxia in prostate cancer. PC3 and DU-145 adenocarcinoma cells, in vitro, were gassed with various oxygen concentrations (0-21%) for 24 h, followed by real-time PCR. Xenografts were established in vivo, and the mice were injected with the hypoxic markers [18F]-FAZA and pimonidazole. Subsequently, tumors were excised, frozen, cryo-sectioned, and analyzed using autoradiography ([18F]-FAZA) and immunohistochemistry (pimonidazole); the autoradiograms used as templates for laser capture microdissection of hypoxic and non-hypoxic areas, which were lysed, and real-time PCR was performed. In vitro, all 15 genes were increasingly up-regulated as oxygen concentrations decreased. With the xenografts, all 15 genes were up-regulated in the hypoxic compared to non-hypoxic areas for both cell lines, although this effect was greater in the DU-145. We have developed a combined autoradiographic/laser-guided microdissection method with broad applicability. Using this approach on fresh frozen tumor material, thereby minimizing the degree of RNA degradation, we showed that the 15-gene hypoxia gene classifier developed in HNSCC may be applicable for adenocarcinomas such as prostate cancer.
Sections du résumé
BACKGROUND
BACKGROUND
This pre-clinical study was designed to refine a dissection method for validating the use of a 15-gene hypoxia classifier, which was previously established for head and neck squamous cell carcinoma (HNSCC) patients, to identify hypoxia in prostate cancer.
METHODS
METHODS
PC3 and DU-145 adenocarcinoma cells, in vitro, were gassed with various oxygen concentrations (0-21%) for 24 h, followed by real-time PCR. Xenografts were established in vivo, and the mice were injected with the hypoxic markers [18F]-FAZA and pimonidazole. Subsequently, tumors were excised, frozen, cryo-sectioned, and analyzed using autoradiography ([18F]-FAZA) and immunohistochemistry (pimonidazole); the autoradiograms used as templates for laser capture microdissection of hypoxic and non-hypoxic areas, which were lysed, and real-time PCR was performed.
RESULTS
RESULTS
In vitro, all 15 genes were increasingly up-regulated as oxygen concentrations decreased. With the xenografts, all 15 genes were up-regulated in the hypoxic compared to non-hypoxic areas for both cell lines, although this effect was greater in the DU-145.
CONCLUSIONS
CONCLUSIONS
We have developed a combined autoradiographic/laser-guided microdissection method with broad applicability. Using this approach on fresh frozen tumor material, thereby minimizing the degree of RNA degradation, we showed that the 15-gene hypoxia gene classifier developed in HNSCC may be applicable for adenocarcinomas such as prostate cancer.
Identifiants
pubmed: 34073301
pii: cancers13112602
doi: 10.3390/cancers13112602
pmc: PMC8198481
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Kræftens Bekæmpelse
ID : R40-A2022-11-S2
Organisme : Sundhed og Sygdom, Det Frie Forskningsråd
ID : DFF - 4004-00362
Références
Acta Oncol. 2017 Nov;56(11):1583-1590
pubmed: 28840765
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Nat Rev Cancer. 2008 Jun;8(6):425-37
pubmed: 18500244
EBioMedicine. 2018 May;31:182-189
pubmed: 29729848
J Radiat Res. 2016 Aug;57 Suppl 1:i90-i98
pubmed: 26983987
Radiother Oncol. 2015 Sep;116(3):346-51
pubmed: 26169282
Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):953-61
pubmed: 2211264
Recent Results Cancer Res. 2016;198:123-42
pubmed: 27318684
Radiother Oncol. 1993 Jul;28(1):69-71
pubmed: 8234872
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
Cancer Res. 1989 Dec 1;49(23):6449-65
pubmed: 2684393
Cancer Res. 2018 Aug 15;78(16):4774-4785
pubmed: 29945958
Br J Cancer. 2015 Jan 20;112(2):382-90
pubmed: 25461803
Lab Invest. 2005 Aug;85(8):1040-50
pubmed: 15951835
Radiat Res. 1999 May;151(5):580-9
pubmed: 10319731
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e433-9
pubmed: 21985947
Acta Oncol. 2010 Oct;49(7):922-33
pubmed: 20831479
Radiat Res. 2008 Jun;169(6):677-88
pubmed: 18494550
Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):186-97
pubmed: 23076620
Br J Radiol. 2014 Mar;87(1035):20130753
pubmed: 24588670
Appl Radiat Isot. 2005 Jun;62(6):897-901
pubmed: 15799867
Cancer Res. 2011 Feb 1;71(3):779-89
pubmed: 21266355
Pharmacol Ther. 2015 Sep;153:107-24
pubmed: 26073310
Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):171-80
pubmed: 10477021
Acta Oncol. 2010 Oct;49(7):895-905
pubmed: 20429727
Oncotarget. 2018 Jan 13;9(11):10005-10015
pubmed: 29515786
Front Oncol. 2020 Apr 21;10:562
pubmed: 32373534
Radiother Oncol. 2012 Jan;102(1):122-9
pubmed: 21996521
Radiother Oncol. 2004 Jan;70(1):91-7
pubmed: 15036858
Int J Radiat Oncol Biol Phys. 1984 May;10(5):695-712
pubmed: 6735758
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):91-9
pubmed: 16563659
Cancer Res. 2011 Sep 1;71(17):5923-31
pubmed: 21846821
Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1065-71
pubmed: 17637389
Nat Rev Clin Oncol. 2012 Dec;9(12):674-87
pubmed: 23149893
Clin Oncol (R Coll Radiol). 2015 Oct;27(10):547-60
pubmed: 26282471
Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1816-23
pubmed: 21833840
Front Oncol. 2016 Apr 12;6:66
pubmed: 27148472
Nat Genet. 2019 Feb;51(2):308-318
pubmed: 30643250
Acta Oncol. 2019 Oct;58(10):1476-1482
pubmed: 31432722
Acta Oncol. 2015;54(9):1385-92
pubmed: 26329662
Clin Cancer Res. 2012 Apr 1;18(7):2108-14
pubmed: 22465832